Single-drug vinorelbine as a salvage re-induction regimen for 4
consecutive pediatric patients with relapsed anaplastic large-cell
lymphoma in a single children's institution
Approximately 20–40% of pediatric patients with anaplastic large-cell
lymphoma (ALCL) develop recurrent disease. Here, we report a pilot
experience using single-drug weekly vinorelbine (25 mg/m2/wk) as a
salvage re-induction regimen in 4 consecutive pediatric patients with
relapsed ALCL. All 4 patients achieved complete remission after 2 cycles
of weekly vinorelbine and were disease-free alive at last evaluation.
The main toxicity was hematologic. Only one week of vinorelbine
administration was withheld for a grade 4 neutropenia in one patient.
The results suggest that weekly vinorelbine has good efficacy and safety
in the treatment of relapsed pediatric ALCL.